July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Firsts steps in the development of a topical CeO2NPs treatment to fight dry AMD progression using the DKOrd8 mouse model
Author Affiliations & Notes
  • Anna Badia
    Ophthalmology, Vall d'Hebron Research Institute, Sabadell, Barcelona, Spain
  • Anna Salas Torras
    Ophthalmology, Vall d'Hebron Research Institute, Sabadell, Barcelona, Spain
  • Ignacio Salvo Ibanez
    Pharmacokinetic Nanoparticles, Vall d'Hebron Research Institute, Barcelona, Barcelona, Spain
  • Barbara Ferreira de Souza
    Ophthalmology, Vall d'Hebron Research Institute, Sabadell, Barcelona, Spain
  • Eudald Casals
    Pharmacokinetic Nanoparticles, Vall d'Hebron Research Institute, Barcelona, Barcelona, Spain
  • Victor Puntes
    Pharmacokinetic Nanoparticles, Vall d'Hebron Research Institute, Barcelona, Barcelona, Spain
  • Miguel Angel Zapata
    Ophthalmology, Vall d'Hebron Research Institute, Sabadell, Barcelona, Spain
  • Laura Fontrodona
    Ophthalmology, Vall d'Hebron Research Institute, Sabadell, Barcelona, Spain
  • Jose Garcia-Arumi
    Ophthalmology, Vall d'Hebron Research Institute, Sabadell, Barcelona, Spain
  • Footnotes
    Commercial Relationships   Anna Badia, None; Anna Salas Torras, None; Ignacio Salvo Ibanez, None; Barbara Ferreira de Souza, None; Eudald Casals, None; Victor Puntes, None; Miguel Zapata, None; Laura Fontrodona, None; Jose Garcia-Arumi, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 58. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Anna Badia, Anna Salas Torras, Ignacio Salvo Ibanez, Barbara Ferreira de Souza, Eudald Casals, Victor Puntes, Miguel Angel Zapata, Laura Fontrodona, Jose Garcia-Arumi; Firsts steps in the development of a topical CeO2NPs treatment to fight dry AMD progression using the DKOrd8 mouse model. Invest. Ophthalmol. Vis. Sci. 2018;59(9):58.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Cerium oxide nanoparticles (CeO2NPs) exhibit a high scavenging ROS activity, making them suitable for the treatment of pathologies with increased oxidative stress, like dry AMD. With the aim to generate a reliable AMD model to assess the efficacy of a CeO2NPs topical therapy, the initial purpose was set in developing the DKOrd8 mouse, testing the efficacy of CeO2NPs in vitro and assessing their biodistribution.

Methods : By crossing three different mouse strains, we generated the Ccl2/Cx3cr1 double knockout (DKO) mouse in C57BL/6N background (with the rd8 mutation) and assessed its retina status and visual function during 9 months through in vivo and post-mortem analyses. In parallel, we synthesized CeO2NPs and evaluated its safety and antioxidant capacity in ARPE19 cell cultures as well as its anti-angiogenic activity in HUVEC cell cultures. We also assessed CeO2NPs biodistribution after topical or intravitreal administration in C57BL/6N mice analyzing cerium concentration in ocular and extraocular tissues through ICP-MS.

Results : The DKOrd8 mice we generated presented disorganized retinal spots as well as a progressive reduction in retinal thickness, identified by histological evaluation and in vivo optical coherence tomography. Immunofluorescence analyses also showed increased expression of GFAP and oxidative stress markers at an early age. In addition, we observed a decreased response to light stimuli compared to C57BL/6N mice, maintained upon ageing.
CeO2NPs-treated cells presented no toxicity and showed a dose-dependent reduction of ROS levels after induction of oxidative stress along with an inhibition of endothelial cells migration. In the biodistribution assay, we detected cerium in the retina, 24h after either intravitreal or topical administration, at a concentration of 98,18ng/mg of tissue and 47,46ng/mg of tissue respectively. Cerium was detected in other parts of the eye but not in extraocular tissues.

Conclusions : CeO2NPs showed strong antioxidant and antiangiogenic properties in vitro and more importantly, they were able to reach the retina at significant levels after a topical administration. DKOrd8 mice presented a progressive retinal degeneration and altered retinal function. Taken together, these results set the base for the upcoming administration of CeO2NPs in the DKOrd8 mouse, which will help us to elucidate the advantages of this promising therapy.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×